维生素D与甲状腺疾病的相关性

doi:10.12092/j.issn.1009-2501.2020.01.014

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (1): 94-100.doi: 10.12092/j.issn.1009-2501.2020.01.014

维生素D与甲状腺疾病的相关性

苏姗^1,2，张迪^1,2，王强梅^1,2，甄东户²

¹兰州大学第一临床医学院，兰州 730000，甘肃；²兰州大学第一医院内分泌科，兰州 730000，甘肃

收稿日期:2019-10-28 修回日期:2019-12-10 出版日期:2020-01-26 发布日期:2020-02-11
通讯作者: 甄东户，女，博士，主任医师，硕士生导师，研究方向：内分泌与代谢性疾病。 Tel：+86-931-8619797 E-mail：zhdh8279@163.com
作者简介:苏姗，女，硕士，研究方向：甲状腺疾病。 Tel：18829073504 E-mail：1334603848@qq.com
基金资助:
甘肃省自然科学基金（1606RGZA347）；中央高校基本科研业务费专项资金重点项目（2022142zrk012）；甘肃省卫生行业科研计划（GSWSKY-2014-27）；兰州大学第一医院院内基金（ldyyyn-2015-23）

Correlation between vitamin D and thyroid disease

SU Shan^1,2, ZHANG Di ^1,2, WANG Qiangmei ^1,2, ZHEN Donghu ²

¹The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; ²Department of endocrinology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China

Received:2019-10-28 Revised:2019-12-10 Online:2020-01-26 Published:2020-02-11

摘要/Abstract

摘要： 维生素D除了具有调节钙磷及骨代谢作用外，免疫调节及抗肿瘤增殖作用逐渐被研究者们提出。目前，大量研究发现患有甲状腺疾病的患者体内维生素D水平较低，并认为维生素D不足/缺乏可能参与甲状腺疾病的发病过程，但二者之间具体的关系及作用机制尚未完全明确。本文旨在对近几年关于维生素D与几种常见的甲状腺疾病相关性的研究进行综述，分析维生素D在甲状腺疾病发病中的作用，以及补充维生素D对甲状腺疾病发生、发展的影响。

关键词: 维生素D, Graves病, 桥本氏甲状腺炎, 甲状腺结节, 甲状腺癌

Abstract: In addition to the role of vitamin D in regulating calcium and phosphorus homeostasis and bone metabolism, immune regulation and anti-tumor proliferation have been gradually proposed by researchers. At present, a large number of studies have found that patients with thyroid diseases have low vitamin D levels, and it is believed that vitamin D insufficiency/ deficiency may be involved in the pathogenesis of thyroid diseases, but the specific relationship and mechanism between vitamin D and thyroid diseases have not been fully clarified. This article reviewed in the relationship between vitamin D and several common thyroid diseases in recent years, in order to analyze the role of vitamin D in the pathogenesis of thyroid diseases, as well as the influence of vitamin D supplementation on the occurrence and development of thyroid diseases.

Key words: vitamin D, Graves' disease, Hashimoto's thyroiditis, thyroid nodules, thyroid cancer

中图分类号:

R581

苏姗，张迪，王强梅，甄东户. 维生素D与甲状腺疾病的相关性[J]. 中国临床药理学与治疗学, 2020, 25(1): 94-100.

SU Shan, ZHANG Di, WANG Qiangmei, ZHEN Donghu. Correlation between vitamin D and thyroid disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 94-100.

参考文献

［1］Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention［J］. Rev Endocr Metab Disord, 2017, 18(2):153-165.
［2］Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications［J］. Chem Biol,2014,21(3):319-329.
［3］Incel Uysal P, Alli N, Hayran Y, et al. Mycosis fungoides and vitamin D status: Analyses of serum 25-hidroxyvitamin D levels and single nucleotide polymorphisms in the vitamin D receptor gene［J］. Acta dermatovenerologica Croatica, 2018, 26(1): 8.
［4］Gil , Plaza-Diaz J, Mesa MD. Vitamin D: Classic and novel actions［J］. Ann Nutr Metab, 2018,72(2):87-95.
［5］Eshaghkhani Y, Sanati MH, Nakhjavani M, et al. Disturbed Th1 and Th2 balance in patients with Graves' disease［J］. Minerva Endocrinol, 2016, 41(1):28-36.
［6］Berg JP, Ree AH, Sandvik JA, et al. 1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase［J］. J Biol Chem,1994,269(51):32233-32238.
［7］Sheikh V, Kasapoglu P, Zamani A, et al. Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+T cell cytokines and upregulate inhibitory markers［J］. Hum Immunol, 2018,79(6):439-445.
［8］Prietl B, Treiber G, Pieber T, et al. Vitamin D and immune function［J］. Nutrients,2013,5(7):2502-2521.
［9］Corripiomiyar Y, Mellanby R J, Morrison K, et al. 1,25-Dihydroxyvitamin D3 modulates the phenotype and function of monocyte derived dendritic cells in cattle［J］. BMC Vet Res,2017,13(1):390.
［10］Misharin A, Hewison M, Chen CR, et al. Vitamin D deficiency modulates graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization［J］. Endocrinology,2009,150(2):1051-1060.
［11］Yasuda T，Miyashita K，Takahara M，et al. Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves disease［J］. Endocrine，2012,42(3):739-741.
［12］Yasuda T，Miyashita K，Takahara M，et al. Serum vitamin D levels are decreased in patients without remission of Graves'disease ［J］. Endocrine,2013,43(1):230-232.
［13］Mangaraj S, Choudhury AK, Swain BM, et al. Evaluation of vitamin D status and its impact on thyroid related parameters in new onset Graves' disease-A cross-sectional observational study［J］. Indian J Endocrinol Metab. 2019,23(1):35-39.
［14］Li X, Wang G, Lu Z, et al. Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves' disease［J］. J Endocrinol Invest, 2015, 38(7):753-759.
［15］Kawakamitani T, Fukawa E, Tanaka H, et al. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease［J］. Metabolism,1977,46(10):1184-1188.
［16］Planck T, Shahida B, Malm J, et al. Vitamin D in Graves disease: Levels, correlation with laboratory and clinical parameters, and genetics［J］. Eur Thyroid J, 2018,7(1):27-33.
［17］Safdari V, Alijani E, Nemati M, et al. Imbalances in T cell-related transcription factors among patients with Hashimoto's thyroiditis［J］. Sultan Qaboos Univ Med J,2017,17(2): 174-180.
［18］tefanic M, Tokic S. Serum 25-hydoxyvitamin D concentrations in relation to Hashimoto's thyroiditis: a systematic review, meta-analysis and meta-regression of observational studies［J］.Eur J Nutr,2019,1-14.
［19］Ucan B, Sahin M, Arslan MS, et al. Vitamin D treatment in patients with Hashimoto's thyroiditis may decrease the development of hypothyroidism［J］. Int J Vitam Nutr Res, 2017, 86(1-2):1-9.
［20］刘杉,熊丰,刘恩梅,等.1，25(OH)2D3干预实验性自身免疫性甲状腺炎TH1/TH2细胞失衡的研究［J］.南方医科大学学报,2010,30(7):1573-1576.
［21］Vahabi PA, Aminorroaya A, Amini M, et al. Effect of vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial［J］. J Res Med Sci, 2017, 22(1):103.
［22］刘茂,王培桦.甲状腺结节影响因素分析［J］.江苏预防医学,2017,28(6):665-667.
［23］Du X, Liu Y, Zhao C, et al. Changes of serum 25(OH) D3 and IGF-1 levels in patients with thyroid nodules［J］. BMC Endocr Disord, 2019, 19(1):48.
［24］王广利, 谭运新. 甲状腺结节患者血清维生素D水平的检测及意义［J］. 世界最新医学信息文摘,2018,18(78):94-99.
［25］闫艳芳. 雌、雄激素和维生素D及其受体在甲状腺结节患者血清及甲状腺组织中的水平［D］. 河北医科大学，2015.
［26］Figge, JJ. Epidemiology of thyroid cancer［M］. New York: Springer, 2016.
［27］Li M, Li L, Zhang L, et al. 1,25-Dihydroxyvitamin D3, suppresses gastric cancer cell growth through VDR- and mutant p53-mediated induction of p21［J］. Life Sci, 2017,179:88-97.
［28］Bandera MB, Morcillo S, MartinNunez G, et al. The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences［J］. J Steroid Biochem Mol Biol, 2017, 167:203-218.
［29］Penna MM, Ramos LE, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma［J］. Carcinogenesis,2009,30(7):1170-1180.
［30］Zhao JY,Wang HP,Zhang ZW, et al. Vitamin D deficiency as a risk factor for thyroid cancer: A meta-analysis of case-control studies［J］. Nutrition, 2019,57:5-11.
［31］Chiang KC, Kuo SF, Chen CH, et al. MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential［J］. Cancer Lett, 2015, 369(1):76-85.
［32］Zhang T, Zhang H, He L, et al. Potential use of 1-25-dihydroxyvitamin D in the diagnosis and treatment of papillary thyroid cancer［J］. Med Sci Monit, 2018, 24:1614-1623.
［33］Ahn HY, Chung YJ, Park KY，et al. Serum 25-hydroxyvitamin D level does not affect the progressiveness and prognosis of papillary thyroid cancer［J］. Thyroid, 2016, 26(3):429-433.

[1]	谢晶晶, 尹鸿涛, 刘进进, 孙蔚明, 甄东户. 基线血清25-羟维生素D3水平与代谢综合征发病风险的前瞻性队列研究[J]. 中国临床药理学与治疗学, 2023, 28(6): 641-652.
[2]	张维, 刘蕾, 管绍羊, 盛昭, 孙雯雯. 细针穿刺细胞学检查以及BRAF、RAS基因突变筛查对甲状腺癌的诊断价值分析[J]. 中国临床药理学与治疗学, 2023, 28(6): 653-657.
[3]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[4]	李晨豪, 喻喜华, 闫文浩, 柴宇霞, 李燕燕, 李锟, 李泽运. 儿童癫痫与维生素D相关性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1299-1306.
[5]	汤佳卫, 孟祥哲, 孙学敏, 李玥轩, 刘雪, 魏红. 维生素D与ACE2在COVID-19中的作用[J]. 中国临床药理学与治疗学, 2022, 27(11): 1292-1298.
[6]	陈文捷, 王亚兵, 陈晓琳, 任俊玲, 赵晚君, 陈斌. 碘难治性分化型甲状腺癌的最新研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 116-120.
[7]	章权, 石仕元, 韩贵和. 1,25二羟维生素D3在脊柱结核治疗中的免疫调节作用[J]. 中国临床药理学与治疗学, 2021, 26(7): 787-793.
[8]	徐永霞, 谢明珠, 宫牧雪, 黄嘉莹, 赵丽, 朱德发. 25羟维生素D对老年2型糖尿病患者胰岛β细胞功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1021-1026.
[9]	李玲，赵慧佳，陈彬尧，刘晓红，孙功鹏，郝卓文，范志鹏，乐江，吴建国，叶啟发. CYP2R1的遗传多态性及其个体化治疗应用[J]. 中国临床药理学与治疗学, 2019, 24(9): 1053-1059.
[10]	唐新月，石峰，黎翠林，刘剑秋，李智. TERT启动子突变在甲状腺癌中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(3): 350-354.
[11]	丁玲，张宇. 维生素D佐治婴幼儿毛细支气管炎的临床研究[J]. 中国临床药理学与治疗学, 2016, 21(2): 214-217.
[12]	沙南南，王拥军，张岩. 维生素D对破骨细胞、成骨细胞分子调控的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(10): 1196-1200.
[13]	王萍, 徐潇静, 卜锋啸, 周宇, 叶安, 周伯庭. EGFR基因rs1024750多态性显著影响钙加维生素D干预绝经后白人妇女的血钙水平[J]. 中国临床药理学与治疗学, 2014, 19(7): 772-779.
[14]	李东, 夏晨梅, 陈霞, 颜海帆, 冯崇炽. 骨化三醇对男性酒精性肝硬化患者骨密度和骨代谢的影响[J]. 中国临床药理学与治疗学, 2014, 19(6): 691-694.
[15]	潘海, 刘金鑫, 张岩. 慢性肾病合并矿物质与骨代谢紊乱的发病机制、临床诊断与治疗[J]. 中国临床药理学与治疗学, 2014, 19(6): 695-700.

维生素D与甲状腺疾病的相关性

Correlation between vitamin D and thyroid disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价